I
I. Herrgott
Researcher at University of Münster
Publications - 7
Citations - 834
I. Herrgott is an academic researcher from University of Münster. The author has contributed to research in topics: Systemic scleroderma & FEV1/FVC ratio. The author has an hindex of 6, co-authored 7 publications receiving 751 citations.
Papers
More filters
Journal ArticleDOI
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan,Jörg H W Distler,Britta Maurer,Dörte Huscher,Jacob M van Laar,Yannick Allanore,Oliver Distler,Tore K Kvien,Paolo Airò,Juan José Alegre Sancho,Lidia Ananjeva,Codrina Michaela Ancuta,Martin Aringer,Alexandra Balbir-Gurman,Francesco Paolo Cantatore,Paola Caramaschi,Emmanuel Chatelus,Veronica Codullo,Dominique Farge-Bancel,Rosario Foti,Armando Gabrielli,Jörg Henes,I. Herrgott,Florenzo Iannone,Francesca Ingegnoli,Esthela Loyo,Marco Matucci-Cerinic,Walid Ahmed Abdel Atty Mohamed,Ulf Müller-Ladner,Øyvind Palm,Sergiu Popa,Gabriela Riemekasten,Simona Rednic,Edoardo Rosato,M. Saracco,Agneta Scheja,Vanessa Smith,Carina Mihai,Gabriela Szucs,Matija Tomšič,Gabriele Valentini,Ulrich A. Walker,Rene Westhovens,Sule Yavuz,Thierry Zenone +44 more
TL;DR: The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis, supporting the therapeutic concept of B cell inhibition in SSc.
Journal ArticleDOI
Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
TL;DR: The high response rate in patients with therapy refractory pruritus suggests that the NKR1 antagonist aprepitant may indeed exhibit antipruritic effects and may present a novel, effective treatment strategy based on pathophysiology of chronicPruritus.
Journal ArticleDOI
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.
Cord Sunderkötter,I. Herrgott,C Brückner,Pia Moinzadeh,Christiane Pfeiffer,J Gerss,Nicolas Hunzelmann,Markus Böhm,T. Krieg,Ulf Müller-Ladner,Ekkehard Genth,Eckhard Schulze-Lohoff,Michael Meurer,Inga Melchers,G. Riemekasten,Dnss Centers +15 more
TL;DR: This work has shown that digital ulcers are a major complication in the course of systemic sclerosis and identifying the risk factors for DU is useful for optimal management.
Journal ArticleDOI
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
Pia Moinzadeh,Elisabeth Aberer,Keihan Ahmadi-Simab,Norbert Blank,J. H. W. Distler,Gerhard Fierlbeck,Ekkehard Genth,C. Guenther,R. Hein,Joerg Henes,Lena Herich,I. Herrgott,I. Koetter,Alexander Kreuter,Thomas Krieg,Kathrin Kuhr,Hanns-Martin Lorenz,Florian M P Meier,Inga Melchers,Hartwig Mensing,Ulf Mueller-Ladner,Christiane Pfeiffer,Gabriela Riemekasten,Miklós Sárdy,Marc Schmalzing,C. Sunderkoetter,Laura Susok,Ingo H. Tarner,Peter Vaith,Margitta Worm,Gottfried Wozel,G. Zeidler,Nicolas Hunzelmann,and all participating Dnss centers +33 more
TL;DR: The concept that SSc-overlap syndromes should be regarded as a separate SSc subset, distinct from lcSSc and dcSSc, due to a different progression of the disease, different proportional distribution of specific autoantibodies, and of different organ involvement is supported.
Journal ArticleDOI
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.
Nicolas Hunzelmann,Gabriela Riemekasten,M.O. Becker,Pia Moinzadeh,Alexander Kreuter,Inga Melchers,Ulf Mueller-Ladner,Florian M P Meier,Margitta Worm,H. Lee,I. Herrgott,Christiane Pfeiffer,Gerhard Fierlbeck,Jörg Henes,Aaron Juche,G. Zeidler,Hartwig Mensing,Claudia Günther,Miklós Sárdy,Harald Burkhardt,M. Koehm,Kathrin Kuhr,T. Krieg,Cord Sunderkötter +23 more
TL;DR: The prevalence of DUs during follow-up did not change, whereas the prevalence of other organ involvement increased substantially over time in the cohort of the German registry, and it is not known what percentage of patients with SSc will develop D Us during further disease evolution.